Evolocumab

Details

Evolocumab (brand: Repatha; Amgen) is a fully human monoclonal IgG2 antibody targeting PCSK9. Subcutaneous administration; FDA-approved for hypercholesterolaemia, HeFH, HoFH, and ASCVD risk reduction.

Key Facts

Dosing

• 140 mg subcutaneously every 2 weeks OR 420 mg monthly; both regimens produce equivalent ~60% LDL-C reduction sources/pcsk9-inhibitors-nrc-2018 (very high)
• No dose adjustment for renal/hepatic impairment in Phase III; LDL-C lowering independent of baseline plasma PCSK9 level

Mechanism and LDL-C Effects

• Fully human mAb → no neutralizing antibody development; durable efficacy maintained over years sources/pcsk9-inhibitors-nrc-2018 (very high)
• ~60% LDL-C reduction in HeFH, statin-intolerant patients, and patients on high-intensity statin (Phase III: MENDEL-2, LAPLACE-2, GAUSS-2/3, RUTHERFORD-2)
• Also reduces: Lp(a) ~25%, ApoB ~50%, TG ~15%; no effect on CRP (in contrast to statins)

HoFH — Genotype-Specific Response

Response is determined by residual LDLR function sources/pcsk9-inhibitors-nrc-2018 (very high):

• Overall HoFH trial (TESLA Part B; double-blind, placebo-controlled): mean 31% LDL-C reduction
• Open-label TAUSSIG extension: 420 mg monthly → 20% reduction; uptitration to 420 mg Q2 weeks → 28% reduction

FOURIER Cardiovascular Outcome Trial

• Design: n=27,564; established ASCVD (prior MI/nonhaemorrhagic stroke/symptomatic PAD); LDL-C ≥70 mg/dL on optimised statin (69% high-intensity); median follow-up 2.2 years
• LDL-C effect: baseline 92 mg/dL → median 30 mg/dL (59% reduction; absolute 56 mg/dL) sources/pcsk9-inhibitors-nrc-2018 (very high)
• Primary endpoint (CV death/MI/stroke/coronary revascularisation/UA hosp): HR 0.85 (95% CI 0.79–0.92)
• Key secondary endpoint (CV death/MI/stroke): HR 0.80 (95% CI 0.73–0.88)
• Specific reductions: fatal/nonfatal MI −21%, fatal/nonfatal stroke −21%, urgent revascularisation −27%, elective revascularisation −13%
• No significant effect on CV death or UA hospitalisation (attributed to 2.2-year follow-up — event curves still diverging)
• Landmark analysis: year 1 CV death/MI/stroke RRR = 16%; after year 1 = 25%

FOURIER — Subgroup Analyses

• Very low baseline LDL-C (<70 mg/dL; n=~3,000): achieved 21 mg/dL; CV death/MI/stroke HR 0.70 (95% CI 0.48–1.01; 30% RRR) — benefit consistent sources/pcsk9-inhibitors-nrc-2018 (very high)
• High-risk coronary subgroups (recent MI, multiple prior MIs, multivessel CAD): baseline risk 40–100% higher; RRR 21–30% vs 11–16% in lower-risk; ARR >3% at 3 years (vs ~1% lower-risk)
• PAD subgroup (n=3,642; 13.2%): 2.5-year CV death/MI/stroke 13.0% vs 7.6%; evolocumab → 27% RRR (similar to non-PAD); ARR 3.5% vs 1.4% (non-PAD); 42% reduction in major adverse limb events (HR 0.58; 95% CI 0.38–0.88; P=0.009)
• Consistent LDL-C reduction achieved LDL-C down to <10 mg/dL in some patients; monotonic relationship between achieved LDL-C and CV outcomes but not safety outcomes

Safety Profile (FOURIER)

• No excess: new-onset diabetes, myalgias, cataracts, haemorrhagic stroke, aminotransferase elevation, neurocognitive events sources/pcsk9-inhibitors-nrc-2018 (very high)
• No excess diabetes even in prediabetes subgroup (contrast to statin DM risk, which is concentrated in prediabetes)
• No neutralizing antibodies (fully human mAb)
• EBBINGHAUS neurocognitive substudy (n=1,974): no between-group differences on Cambridge Neuropsychological Test Automated Battery; no association between achieved LDL-C and cognitive performance
• Injection-site reactions: 0.2%/year excess (mostly mild)

Contradictions / Open Questions

• No cardiovascular mortality reduction in FOURIER; ODYSSEY Outcomes (alirocumab) showed only a nominal all-cause mortality trend; longer follow-up required before definitive mortality claims
• Evolocumab had NO effect on CRP (high-sensitivity assay) in FOURIER, contradicting preclinical evidence that PCSK9 drives macrophage TLR4/NF-κB inflammation independently of LDL-R. In vitro: evolocumab prevents H2O2-induced cytotoxicity and reduces hydroperoxides/malondialdehyde in endothelial cells — but this antioxidant effect has not translated to clinical biomarker changes sources/pcsk9-jaha-2022 (medium)
• In one imaging study, evolocumab did NOT affect coronary plaque composition, despite PCSK9's proposed direct role in plaque inflammation (conflicting with one clinical study showing PCSK9 correlates with necrotic core content independent of LDL-C) sources/pcsk9-jaha-2022 (medium)
• Mendelian randomization studies suggest PCSK9 LoF variants associated with diabetes risk — not replicated in 2.2-year FOURIER (long-term surveillance required) sources/pcsk9-inhibitors-nrc-2018 (very high)
• HoFH patients with null-null LDLR genotype derive no benefit — alternative therapies (evinacumab, lomitapide, apheresis) required concepts/ANGPTL3-Inhibition

Connections

• Related to concepts/PCSK9-Inhibitors — class overview
• Related to entities/Alirocumab — companion PCSK9 mAb
• Related to entities/Inclisiran — siRNA PCSK9 inhibitor
• Related to concepts/Familial-Hypercholesterolemia — HoFH/HeFH use
• Related to concepts/PAD-Medical-Therapy — major adverse limb event reduction
• Related to concepts/Dyslipidemia-Management — position in treatment algorithm

Sources

• sources/pcsk9-inhibitors-nrc-2018 (very high)
• sources/pcsk9-jaha-2022 — in vitro antioxidant effect; no CRP reduction in FOURIER; no plaque composition change in imaging study (medium)